Advertisement

Malaise, Laryngitis and Fever

  • Claus-Philipp Maier
  • Dominik SchneidawindEmail author
Chapter

Abstract

  • Acute myeloid leukemia (AML) with inv(16) or t(16;16) is generally associated with a more favorable prognosis and a high percentage of complete remission

  • Risk factors for central nervous system (CNS) involvement in pediatric AML include high WBC count, younger age and AML with inv(16)

Keywords

Acute myeloid leukemia Induction Remission Daunorubicin Cytarabine 

References

  1. 1.
    European Conference on Infections in Leukaemia (ECIL) guidelines 1–6. www.ecil-leukaemia.com.
  2. 2.
    Firpi R, Nelson D. Management of viral hepatitis in hematologic malignancies. Blood Rev. 2008;22(3):117–26.CrossRefGoogle Scholar
  3. 3.
    Grimwade D, Hills RK, Moorman AV, Walker H, Chatters S, Goldstone AH, Wheatley K, Harrison CJ, Group AKBobotNCRIALW. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010;116(3):354–65.CrossRefGoogle Scholar
  4. 4.
    Döhner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Büchner T, Dombret H, Ebert BL, Fenaux P, Larson RA, Levine RL, Lo-Coco F, Naoe T, Niederwieser D, Ossenkoppele GJ, Sanz M, Sierra J, Tallman MS, Tien H-F, Wei AH, Löwenberg B, Bloomfield CD. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424–47.CrossRefGoogle Scholar
  5. 5.
    Creutzig U, van den Heuvel-Eibrink M, Gibson B, Dworzak MN, Adachi S, de Bont E, Harbott J, Hasle H, Johnston D, Kinoshita A, Lehrnbecher T, Leverger G, Mejstrikova E, Meshinchi S, Pession A, Raimondi S, Sung L, Stary J, Zwaan C, GJL K, Group DRobotACotIBS. Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendation from an international expert panel. Blood. 2012;120(16):3187–205.CrossRefGoogle Scholar
  6. 6.
    Boissel N, Renneville A, Leguay T, Lefebvre PC, Recher C, Lecerf T, Delabesse E, Berthon C, Blanchet O, Prebet T, Pautas C, Chevallier P, Leprêtre S, Girault S, Bonmati C, Guièze R, Himberlin C, Randriamalala E, Preudhomme C, Jourdan E, Dombret H, Ifrah N. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: a French Acute Myeloid Leukemia Intergroup trial. Haematologica. 2015;100(6):780–5.CrossRefGoogle Scholar
  7. 7.
    Pfeiffer T, Schleuning M, Mayer J, Haude K-H, Tischer J, Buchholz S, Bunjes D, Bug G, Holler E, Meyer RG, Greinix H, Scheid C, Christopeit M, Schnittger S, Braess J, Schlimok G, Spiekermann K, Ganser A, Kolb H-J, Schmid C. Influence of molecular subgroups on outcome of acute myeloid leukemia with normal karyotype in 141 patients undergoing salvage allogeneic stem cell transplantation in primary induction failure or beyond first relapse. Haematologica. 2013;98(4):518–25.CrossRefGoogle Scholar
  8. 8.
    Schmid C, Schleuning M, Ledderose G, Tischer J, Kolb H-J. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675–87.CrossRefGoogle Scholar
  9. 9.
    Schmid C, Schleuning M, Schwerdtfeger R, Hertenstein B, Mischak-Weissinger E, Bunjes D, Sv H, Scheid C, Holtick U, Greinix H, Keil F, Schneider B, Sandherr M, Bug G, Tischer J, Ledderose G, Hallek M, Hiddemann W, Kolb H-J. Long term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced intensity conditioning for allogeneic stem cell transplantation. Blood. 2006;108(3):1092–9.CrossRefGoogle Scholar
  10. 10.
    Creutzig U, Dworzak MN, Zimmermann M, Reinhardt D, Sramkova L, Bourquin JP, Hasle H, Abrahamsson J, Kaspers G. Characteristics and outcome in patients with central nervous system involvement treated in European pediatric acute myeloid leukemia study groups. Pediatr Blood Cancer. 2017;64(12):e26664.CrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Internal Medicine IIUniversity Hospital TuebingenTuebingenGermany

Personalised recommendations